MA38417B1 - Substituted oxopyridine Derivatives and Use of Such Derivatives in the Treatment of Cardiovascular Diseases - Google Patents
Substituted oxopyridine Derivatives and Use of Such Derivatives in the Treatment of Cardiovascular DiseasesInfo
- Publication number
- MA38417B1 MA38417B1 MA38417A MA38417A MA38417B1 MA 38417 B1 MA38417 B1 MA 38417B1 MA 38417 A MA38417 A MA 38417A MA 38417 A MA38417 A MA 38417A MA 38417 B1 MA38417 B1 MA 38417B1
- Authority
- MA
- Morocco
- Prior art keywords
- derivatives
- treatment
- diseases
- oxopyridine
- cardiovascular diseases
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- -1 methoxy, difluoromethoxy Chemical group 0.000 abstract 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- 229910052794 bromium Inorganic materials 0.000 abstract 2
- 125000001246 bromo group Chemical group Br* 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Chemical group 0.000 abstract 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Chemical group 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 208000005189 Embolism Diseases 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 150000001923 cyclic compounds Chemical class 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des dérivés de l'oxopyridine subsitués de la formule, dans laquelle : r1 représente un groupe de la formule, * représentant le point de liaison au composé cyclique de l'oxopyridine ; r6 représente du brome, du chlore, du fluor, un groupe méthyle, difluorométhyle, trifluorométhyle, méthoxy, difluorométhoxy ou trifluorométhoxy ; r7 représente du brome, du chlore, du fluor, un groupe cyano, nitro, hydroxy, méthyle, difluorométhyle, trifluorométhyle, méthoxy, éthoxy, difluorométhoxy ou trifluorométhoxy, un groupe éthinyle, un 3,3,3-trifluoroprop-l-in-l-yl ou un groupe cyclopropyle. L'invention concerne également un procédé servant à fabriquer lesdits dérivés de l'oxopyridine, ainsi que leur utilisation pour la fabrication de médicaments servant au traitement et/ou à la prophylaxie de maladies, en particulier de maladies cardiovasculaires, de préférence de maladies thrombotiques ou thrombo-emboliques ou d'oedèmes, ainsi qu'au traitement et/ou à la prophylaxie de maladies ophtalmologiques.The invention relates to substituted oxopyridine derivatives of the formula, wherein: r1 represents a group of the formula, * representing the point of attachment to the cyclic compound of oxopyridine; r6 represents bromine, chlorine, fluorine, methyl, difluoromethyl, trifluoromethyl, methoxy, difluoromethoxy or trifluoromethoxy; r7 is bromine, chlorine, fluorine, cyano, nitro, hydroxy, methyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy or trifluoromethoxy, ethinyl, 3,3,3-trifluoroprop-1-1 1-yl or a cyclopropyl group. The invention also relates to a process for producing said oxopyridine derivatives and their use for the manufacture of medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular diseases, preferably thrombotic diseases or thromboembolism or edema, and the treatment and / or prophylaxis of ophthalmological diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13161588 | 2013-03-28 | ||
| PCT/EP2014/056135 WO2014154794A1 (en) | 2013-03-28 | 2014-03-27 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38417A1 MA38417A1 (en) | 2017-02-28 |
| MA38417B1 true MA38417B1 (en) | 2017-10-31 |
Family
ID=47997233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38417A MA38417B1 (en) | 2013-03-28 | 2014-03-27 | Substituted oxopyridine Derivatives and Use of Such Derivatives in the Treatment of Cardiovascular Diseases |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR095921A1 (en) |
| MA (1) | MA38417B1 (en) |
-
2014
- 2014-03-27 MA MA38417A patent/MA38417B1/en unknown
- 2014-03-27 AR ARP140101397A patent/AR095921A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR095921A1 (en) | 2015-11-25 |
| MA38417A1 (en) | 2017-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502249A1 (en) | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | |
| MA35432B1 (en) | Compound for the treatment and prophylaxis of respiratory syncytial virus disease | |
| MA42376A (en) | SUBSTITUTED OXOPYRIDINE DERIVATIVES | |
| MA38365A1 (en) | Ringed pyrimidines with trifluoromethyl substitution and corresponding use | |
| JO3018B1 (en) | 4-aryl-1, 4-dihydro-1, 6-naphtheridine amides substituted and used | |
| MA47368B1 (en) | N- [4-fluoro-5 - [[(2s, 4s) -2-methyl-4 - [(5-methyl-1,2,4-oxadiazol-3-yl) methoxy] -1-piperidyl] methyl] thiazol-2-yl] acetamide used as an inhibitor of yoga | |
| MA35365B1 (en) | Ringed Pyrimidines substituted and their use | |
| MA39193A1 (en) | Gpr6 modulators based on tetrahydropyridopyrazines | |
| MA35844B1 (en) | Pyrimidines and substituted ringed triazines and their use | |
| MX2016003582A (en) | Compound inhibiting kinase activities of btk and/or jak3. | |
| MA34248B1 (en) | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | |
| PE20170464A1 (en) | ALZHEIMER COMBINATION THERAPY USING AN ABETA ANTI-N3PGLU MONOCLONAL ANTIBODY PLUS A BACE INHIBITOR | |
| MA41238B1 (en) | 5 - [(piperazin-1-yl) -3-oxo-propyl] -imidazolidine-2,4-dione derivatives as adamt inhibitors for the treatment of osteoarthritis | |
| WO2019007696A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| EP2666471A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RATE AND STOMACH, AND METHOD FOR THE PREPARATION THEREOF | |
| MA47356A1 (en) | Isochromene derivatives useful as inhibitors of phosphoinositide 3-kinases | |
| MA38349A1 (en) | Estra-1,3,5 (10), 16-tetraeno-3-carboxamide to inhibit 17-beta-hydroxysteroid dehydrogenase (akr1c3) | |
| MA39171A1 (en) | Hydroxy formamide derivatives and their use | |
| MA40886B1 (en) | Novel c-3 triterpenone with c-28 reverse amide derivatives as hiv inhibitors | |
| MA39983A (en) | CARBOXAMIDE DERIVATIVES | |
| EA201390180A1 (en) | CONDENSED CYCLIC COMPOUNDS OF Pyridine | |
| MA37700B1 (en) | N- [4- (quinolin-4-yloxy) cyclohexyl (methyl)] (hetero) arylcarboxamides for use as androgen receptor antagonists, their production and their use as medicaments | |
| MA46235B1 (en) | 1-aryl-naphthyridin-3-ylcarboxamides substituted in position 7 and their use | |
| ATE380188T1 (en) | SUBSTITUTED QUINOLONES | |
| MA38417B1 (en) | Substituted oxopyridine Derivatives and Use of Such Derivatives in the Treatment of Cardiovascular Diseases |